Literature DB >> 21541642

Association of K-ras codon 12 transversions with short survival in non-small cell lung cancer.

F Vega1, P Iniesta, T Caldes, A Sanchez, J Lopez, C Dejuan, E Diazrubio, A Torres, J Balibrea, M Benito.   

Abstract

K-ras activating point mutations appear to have a role in human lung cancer, however, the prognostic significance of these abnormalities remains unclear. The aim of our work was to clarify the role of K-ras mutations as prognostic indicators in patients affected by non-small cell lung cancer (NSCLC). We studied 94 resected primary NSCLCs for K-ras mutations by the PCR-RFLP technique, followed by sequencing. K-ras activating mutations were present in 34% of tumors, a higher incidence being detected in adenocarcinomas. Comparing the impact of K-ras mutation types, we found that K-ras transversions were associated with a shorter survival in NSCLC.

Entities:  

Year:  1996        PMID: 21541642     DOI: 10.3892/ijo.9.6.1307

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.

Authors:  Ondrej Fiala; Tomas Buchler; Beatrice Mohelnikova-Duchonova; Bohuslav Melichar; Vit Martin Matejka; Lubos Holubec; Jana Kulhankova; Zbynek Bortlicek; Marie Bartouskova; Vaclav Liska; Ondrej Topolcan; Monika Sedivcova; Jindrich Finek
Journal:  Tumour Biol       Date:  2015-12-10

2.  Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer.

Authors:  Takeshi Ogura; Kenji Yamao; Kazuo Hara; Nobumasa Mizuno; Susumu Hijioka; Hiroshi Imaoka; Akira Sawaki; Yasumasa Niwa; Masahiro Tajika; Shinya Kondo; Tsutomu Tanaka; Yasuhiro Shimizu; Vikram Bhatia; Kazuhide Higuchi; Waki Hosoda; Yasushi Yatabe
Journal:  J Gastroenterol       Date:  2012-09-15       Impact factor: 7.527

Review 3.  Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions.

Authors:  Mauricio Burotto; Anish Thomas; Deepa Subramaniam; Giuseppe Giaccone; Arun Rajan
Journal:  J Thorac Oncol       Date:  2014-11       Impact factor: 15.609

Review 4.  Human aldo-keto reductases and the metabolic activation of polycyclic aromatic hydrocarbons.

Authors:  Trevor M Penning
Journal:  Chem Res Toxicol       Date:  2014-10-16       Impact factor: 3.739

Review 5.  Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer.

Authors:  Alia Daoud; Quincy S Chu
Journal:  Front Oncol       Date:  2017-09-29       Impact factor: 6.244

6.  Differences in gynecologic tumor development in Amhr2-Cre mice with KRASG12D or KRASG12V mutations.

Authors:  Eucharist H S Kun; Yvonne T M Tsang; Sophia Lin; Sophia Pan; Tejas Medapalli; Anais Malpica; JoAnne S Richards; David M Gershenson; Kwong-Kwok Wong
Journal:  Sci Rep       Date:  2020-11-26       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.